Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Polymyalgia rheumatica" patented technology

Inflammatory disease which results in muscle ache and stiffness around shoulder.

SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Urea and thiourea compounds and compositions for cholesterol management and related uses

The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis/polymyalgia rheumatica/fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS

Rheumatoid arthritis marker

The present invention addresses the problem of providing a method whereby disease activity of rheumatoid arthritis is evaluated reliably and with good sensitivity by a simple method, and a kit for use in the method. The present invention furthermore provides a method for accurate diagnosis of polymyalgia rheumatica and relapsing polychondritis, which are similar rheumatic diseases, a method for differentiating rheumatoid arthritis, and a kit for use in the same. The present invention provides a Jacalin-binding O-linked oligosaccharide epitope as a negative marker for diagnosing rheumatoid arthritis, and enables more accurate assessment of disease condition by more objectively determining disease activity of rheumatoid arthritis using the amount of variation of a value obtained by multiplying the amount of MMP-3 in the blood or the amount of bound MMP-3 and ABA, ACA, or ACG in the blood by the reciprocal of the amount of bound MMP-3 and Jacalin in the blood. Through the discovery that an LEL or STL-reactive sugar chain on MMP-3 in the blood is a sugar chain marker for diagnosing polymyalgia rheumatica and relapsing polychondritis, the present invention also provides a method for accurate diagnosis of polymyalgia rheumatica and relapsing polychondritis. The present invention furthermore provides a method for accurate diagnosis of rheumatoid arthritis capable of differentiating between similar rheumatic diseases, by measuring the ratio of the amount of LEL or STL bound on MMP-3 and the amount of Jacalin, ACG, or the like bound on MMP-3 in the blood.
Owner:NAT INST OF ADVANCED IND SCI & TECH +2

Methods and Means for Diagnosing Vasculitis

The present inventions relates generally to methods for diagnosing the presence or the risk of development or the therapy control of vasculitis, in particular, of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR) and Takayasu's arteritis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. The presence of antibodies against ferritin or immunoreactive peptides thereof is indicative for the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis. In particular, detection of the presence of antibodies against ferritin or immunoreactive peptides thereof, allows early diagnosis of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER

Traditional Chinese medicine for treating polymyalgia rheumatica and applications of traditional Chinese medicine

The invention discloses a traditional Chinese medicine for treating polymyalgia rheumatica and application of the traditional Chinese medicine, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine is prepared from the following traditional Chinese medicinal materials: cinnamomum wilsonii gamble, rhizoma corydalis decumbentis, semiliquidambar cathayensis, gentiana sarcorrhiza ling et ma, ficus fulva reinw., denseflower bulbophyllum herb, bulbophvl-lum calodictyon schltr, semen sinapis albae, and gaultheria pyroloides. According to the traditional Chinese medicine, the monarch and subjects of the formula are combined and are complementary with each other, and the traditional Chinese medicine has the efficacies of warming channels and expelling cold, activating meridians to stop pain, dispelling the wind and removing dampness, invigorating spleen and supplementing qi, and tonifying the kidney and moistening the lung, and has the significant effects of fast taking effect and treating the symptoms and the causes when used for treating polymyalgia rheumatica. Compared with the traditional Chinese medicine composition in the prior art, the traditional Chinese medicine has the marked technical advantages of fast taking effect, treating the symptoms and the causes and the like, and is convenient and easy, free from any toxic or side effects.
Owner:崔合芳

Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators

The present invention relates to compounds of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Traditional Chinese medicine pills for treating polymyalgia rheumatica

ActiveCN105770834AGood curative effectThe rule of thumb is clearAntipyreticAnalgesicsCodonopsisCurative effect
The invention relates to traditional Chinese medicine pills for treating polymyalgia rheumatica and belongs to the technical field of Chinese herbal medicine. The traditional Chinese medicine pills comprise radix pueraiae, ramulus cinnamomi, adenophora tetraphylla, radix glycyrrhizae, radix paeoniae alba, ginger, angelica sinensis, rhizoma chuanxiong, radix polygonati officinalis, rhizoma atractylodis macrocephalae, rhizoma dioscoreae, radix aconiti lateralis preparata, radix cyathulae, radix achyranthis bidentatae, rhizoma drynariae, radix dipsaci, lycopodium clavatum, saposhnikovia divaricata, radix astragali, radix codonopsis and panax notoginseng. A preparation method of the traditional Chinese medicine pills includes: heating the traditional Chinese medicine materials with microwaves for sterilizing for 5 minutes, crushing with a crusher, sieving with a 100-mesh sieve, dehumidifying, and preparing into the traditional Chinese medicine pills according to weight ratio of the medicine materials to processed honey of 1:1. The traditional Chinese medicine pills have effects of promoting blood circulation to remove blood stasis, dispelling wind and eliminating dampness, relieving muscles analgesia and the like, are good in curative effect, convenient to take, safe and reliable and capable of treating both the symptoms and root causes, overcome the defects of existing medicine for treating the polymyalgia rheumatica, and are significant to the treatment of the polymyalgia rheumatica.
Owner:深圳市晋韬科技有限公司

A traditional Chinese medicine pill for treating polymyalgia rheumatica

The invention relates to traditional Chinese medicine pills for treating polymyalgia rheumatica and belongs to the technical field of Chinese herbal medicine. The traditional Chinese medicine pills comprise radix pueraiae, ramulus cinnamomi, adenophora tetraphylla, radix glycyrrhizae, radix paeoniae alba, ginger, angelica sinensis, rhizoma chuanxiong, radix polygonati officinalis, rhizoma atractylodis macrocephalae, rhizoma dioscoreae, radix aconiti lateralis preparata, radix cyathulae, radix achyranthis bidentatae, rhizoma drynariae, radix dipsaci, lycopodium clavatum, saposhnikovia divaricata, radix astragali, radix codonopsis and panax notoginseng. A preparation method of the traditional Chinese medicine pills includes: heating the traditional Chinese medicine materials with microwaves for sterilizing for 5 minutes, crushing with a crusher, sieving with a 100-mesh sieve, dehumidifying, and preparing into the traditional Chinese medicine pills according to weight ratio of the medicine materials to processed honey of 1:1. The traditional Chinese medicine pills have effects of promoting blood circulation to remove blood stasis, dispelling wind and eliminating dampness, relieving muscles analgesia and the like, are good in curative effect, convenient to take, safe and reliable and capable of treating both the symptoms and root causes, overcome the defects of existing medicine for treating the polymyalgia rheumatica, and are significant to the treatment of the polymyalgia rheumatica.
Owner:深圳市晋韬科技有限公司

Traditional Chinese medicine preparation for treating polymyalgia rheumatica and preparation method thereof

The invention discloses a traditional Chinese medicine preparation for treating polymyalgia rheumatica and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The effective ingredient of the traditional Chinese medicine preparation is prepared from the following raw materials: rhizoma atractylodis macrocephalae, hempleaf negundo chastetree leaves, cassia twigs, kudzu vine roots, ligusticum wallichii, scutellaria indica, sassafras tsumu, passiflora wilsonii, flat-stemmed tetrastigma, trichosanthes palmata, azoila imbricata, parmelia tinctourium, pinus tabulaeformis, rodgersia sambucifolia hemsl, saposhnicovia divaricata and urena lobata. The traditional Chinese medicine preparation is prepared from traditional Chinese medicinal materials with effects of clearing heat, removing toxicity, expelling the evils in muscles by means of diaphoresis, dispelling wind, drying dampness and relieving pain, has the effects of relaxing tendons, activating collaterals, promoting circulation of blood and qi, warmly invigorating pulse-beat, removing stasis and diminishing swelling, is convenient to use, and has good absorption effect and no adverse, toxic or side effect. Clinical application verifies that the traditional Chinese medicine preparation has an extremely good effect for relieving and treating polymyalgia rheumatica, and is applicable to clinical treating and nursing popularization and application of polymyalgia rheumatica.
Owner:王琴华

Aminothiazolones as estrogen related receptor-alpha modulators

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products